PitchSend

Investor Presentaiton

For personal use only CUPID trial Next-generation alpha therapy, complements TLX591 CUPID • • • Study with 64 Cu-TLX592 to show biodistribution and tumour targeting prior to targeted alpha therapy (TAT) with 225 Ac-TLX592 Eligible Patients Prostate cancer patients with low-burden metastatic disease at ≤ 5 sites as detected using PSMA PET/CT scanning (TLX591-CDX) 64 Cu-TLX592 PET/CT scan 225 AC-TLX592 TAT Subject to positive outcomes with 64Cu TELIX PHARMACEUTICALS TAT is becoming an important area of PSMA therapy research, particularly in men that are no longer responding to 177 Lu TLX592 antibody re-engineered to clear ~10x faster from the body, while maintaining specificity for tumour-expressed PSMA (liver cleared, no exocrine uptake) Designed for delivering TAT (225Ac) intended for: • Early-stage metastatic disease (e.g. biochemical recurrence (BCR)) • Late-stage disease when 177 Lu-PSMA therapy is no longer providing treatment efficacy Single arm, open-label, first-in-human (FIH) study of 64 Cu-TLX592 in men with metastatic prostate cancer using PET . Primary endpoint: Determine the safety and tolerability, pharmacokinetics, whole body biodistribution and radiation dosimetry of 64 Cu-TLX592 using PET as a proxy for 225 Ac-TLX592 TAT Status: Actively recruiting - multiple patients dosed in imaging phase Telix Pharmaceuticals Limited (ASX: TLX) 37

View entire presentation